home / stock / apvo / apvo news

APVO News and Press, Aptevo Therapeutics Inc. From 11/12/21

Stock Information
Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com
Menu
APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...
APVO - Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...
APVO - Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") today announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4...

APVO - Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting

Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing...

APVO - BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advan...
APVO - Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021

SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technol...

APVO - Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436

SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technol...

APVO - Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for targeting both MDS clones and immunosuppressive myeloid-derived suppressor cells in high-...
APVO - Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was published in the prestigious oncology journal Cancers SEATTLE, WA / ACCESSWIRE / Au...

APVO - Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technolo...

APVO - China SXT Pharmaceuticals, Trinity Biotech leads healthcare gainers; FibroGen, Neptune Wellness Solutions among major losers

Gainers: China SXT Pharmaceuticals (SXTC) +37%, Trinity Biotech (TRIB) +11%, Moderna (MRNA) +9%, Aptevo Therapeutics (APVO) +9%, Apollo Medical (AMEH) +4%.Losers: FibroGen (FGEN) -45%, Neptune Wellness Solutions (NEPT) -20%, Atossa Therapeutic...
Previous 10 Next 10